354 related articles for article (PubMed ID: 21143503)
21. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
[TBL] [Abstract][Full Text] [Related]
22. Can Mechanistic Static Models for Drug-Drug Interactions Support Regulatory Filing for Study Waivers and Label Recommendations?
Gomez-Mantilla JD; Huang F; Peters SA
Clin Pharmacokinet; 2023 Mar; 62(3):457-480. PubMed ID: 36752991
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of Two-Compartment Model-Assisted and Static Overall Inhibitory-Activity Method for Prediction of Drug-Drug Interaction.
Iga K; Kiriyama A
Biol Pharm Bull; 2017 Dec; 40(12):2024-2037. PubMed ID: 28993551
[TBL] [Abstract][Full Text] [Related]
24. Impact of ignoring extraction ratio when predicting drug-drug interactions, fraction metabolized, and intestinal first-pass contribution.
Kirby BJ; Unadkat JD
Drug Metab Dispos; 2010 Nov; 38(11):1926-33. PubMed ID: 20724498
[TBL] [Abstract][Full Text] [Related]
25. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.
Ohno Y; Hisaka A; Ueno M; Suzuki H
Clin Pharmacokinet; 2008; 47(10):669-80. PubMed ID: 18783297
[TBL] [Abstract][Full Text] [Related]
26. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
27. Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).
Duan P; Zhao P; Zhang L
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):689-705. PubMed ID: 27858342
[TBL] [Abstract][Full Text] [Related]
28. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
29. Prediction of Drug-Drug Interactions Between Opioids and Overdosed Benzodiazepines Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation.
Ji B; Liu S; Xue Y; He X; Man VH; Xie XQ; Wang J
Drugs R D; 2019 Sep; 19(3):297-305. PubMed ID: 31482303
[TBL] [Abstract][Full Text] [Related]
30. In vivo information-guided prediction approach for assessing the risks of drug-drug interactions associated with circulating inhibitory metabolites.
Hu ZY; Parker RB; Laizure SC
Drug Metab Dispos; 2012 Aug; 40(8):1487-94. PubMed ID: 22563046
[TBL] [Abstract][Full Text] [Related]
31. Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors.
Wang YH
Drug Metab Dispos; 2010 Jul; 38(7):1094-104. PubMed ID: 20368327
[TBL] [Abstract][Full Text] [Related]
32. Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.
Boulenc X; Barberan O
Drug Metabol Drug Interact; 2011; 26(4):147-68. PubMed ID: 22149659
[TBL] [Abstract][Full Text] [Related]
33. A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions.
Conner TM; Reed RC; Zhang T
Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):389-408. PubMed ID: 30460522
[TBL] [Abstract][Full Text] [Related]
34. Static Model-Based Assessment of OATP1B1-Mediated Drug Interactions with Preincubation-Dependent Inhibitors Based on Inactivation and Recovery Kinetics.
Taguchi T; Masuo Y; Futatsugi A; Kato Y
Drug Metab Dispos; 2020 Sep; 48(9):750-758. PubMed ID: 32616544
[TBL] [Abstract][Full Text] [Related]
35. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
Chen Y; Mao J; Hop CE
Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
[TBL] [Abstract][Full Text] [Related]
36. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
Eur J Pharm Sci; 2021 Oct; 165():105932. PubMed ID: 34260894
[TBL] [Abstract][Full Text] [Related]
37. Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.
Chen Y; Ma F; Lu T; Budha N; Jin JY; Kenny JR; Wong H; Hop CE; Mao J
Clin Pharmacokinet; 2016 Jun; 55(6):735-49. PubMed ID: 26692192
[TBL] [Abstract][Full Text] [Related]
38. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
Yamazaki S; Johnson TR; Smith BJ
Drug Metab Dispos; 2015 Oct; 43(10):1417-29. PubMed ID: 26180127
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis.
Svensson EM; Acharya C; Clauson B; Dooley KE; Karlsson MO
AAPS J; 2016 Jan; 18(1):171-9. PubMed ID: 26463060
[TBL] [Abstract][Full Text] [Related]
40. Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.
Prieto Garcia L; Janzén D; Kanebratt KP; Ericsson H; Lennernäs H; Lundahl A
Drug Metab Dispos; 2018 Oct; 46(10):1420-1433. PubMed ID: 30068519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
